A Prospective Observational Study of clinical use of Imeglimin for type 2 diabetes mellitus

A Prospective Observational Study of clinical use of Imeglimin for type 2 diabetes mellitus - A Prospective Observational Study of clinical use of Imeglimin for type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046316

Enrollment

Registered

2021-12-10

Start date

2022-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who is clinically planned to start imeglimin treatment. 1) Clinically diagnosed type 2 diabetes mellitus 2) Age >= 20 years old 3) Written informed consent 4) HbA1c < 10.5%, eGFR >=45 mL/min/1.73m2

Exclusion criteria

Exclusion criteria: 1) Allergy against imeglimin 2) Severe ketosis, coma, type 1 diabetes 3) Severe infection, surgery, injury 4) eGFR < 45 mL/min/1.73m2 5) Severe liver dysfunction (Child-Pugh C) 6) Subjects with pregnancy or lactation 7) Use of Insulin 8) Others who medical doctors judge as inappropriate subjects for imeglimin use.

Design outcomes

Primary

Measure	Time frame
HbA1c in 3 months after imeglimin initiation	—

Countries

Japan

Contacts

Public ContactTakaaki Murakami

Kyoto University Hospital Department of Diabetes, Endocrinology, and Nutrition

tmurakam@kuhp.kyoto-u.ac.jp075-751-3560

Outcome results